REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Companyâs NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Companyâs mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Companyâs NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Companyâs third-party licensees. Source
No articles found.
Cyndescope Inc. is a technology company focusing on software solutions for the hea...
Cyndescope Inc. is a technology company focusin...
Tonix is a clinical-stage biopharmaceutical company focused on discovering and dev...
Tonix is a clinical-stage biopharmaceutical com...
Luna (NASDAQ:LUNA) develops and manufactures new-generation products for the healt...
Luna (NASDAQ:LUNA) develops and manufactures ne...
Digirad delivers convenient, effective, and efficient healthcare solutions on an a...
Digirad delivers convenient, effective, and eff...
DermTech is the global leader in molecular dermatology, bringing precision medicin...
DermTech is the global leader in molecular derm...
Intersect ENT (NASDAQ: XENT) is a medical technology company dedicated to advancin...
Intersect ENT (NASDAQ: XENT) is a medical techn...
Benitec is a biotechnology company developing a proprietary therapeutic technology...
Benitec is a biotechnology company developing a...
Join the National Investor Network and get the latest information with your interests in mind.